A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Shanghai Jiao Tong University

Status: Not yet enrolling

Conditions: Extranodal Lymphoma; Marginal Zone Lymphoma; Intravascular Large B-Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Lymphoma; Diffuse Large B Cell Lymphoma; Mucosa-Associated Lymphoid Tissue Lymphoma; NK/T-Cell Lymphoma, Nasal and Nasal-Type

Treatments: Other: No interventions need to be specified for this study

Study type: Observational

Funder types: Other

Identifiers

NCT05907447

EXPECT-01

Details and patient eligibility

About

The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.

Full description

Lymphoma is a highly common malignant tumor in Asia. For specific extra-abdominal sites or rare pathological subtypes of lymphoma, traditional chemotherapy protocols often cannot provide satisfactory results for patients. This study aims to retrospectively collect clinical information on patients with extranodal lymphoma or rare pathological subtype lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best treatment strategy for these lymphomas in the real-world population.

Enrollment: 10,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 years (including 18 years old).
2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined; Or patients newly diagnosed with non-Hodgkin lymphoma of rare pathological types, including IVLBCL, SMZL, ALCL, AITL, MALTL.
3. Patients who have received systematic clinical treatment.
4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.

Exclusion criteria

1. Patients who only receive supportive treatment.
2. Patients who cannot obtain effective evaluation data of efficacy.